RSLS OBALON THERAPEUTICS INC

ReShape Lifesciences™ to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update

ReShape Lifesciences™ to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update

Conference Call to be Held at 4:30 pm ET on Monday, August 15 , 2022

SAN CLEMENTE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2022, including a corporate update, on Monday, August 15, 2022, after-market.

Management will host a conference call on August 15 at 4:30 pm ET. A live webcast will be available on the “Events and Presentations” section of ReShape’s website at: . To access the call by phone, please register with the following , and dial-in details will be provided. Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.

An archived replay will also be available on the “Events and Presentations” section of ReShape’s website at: .

About ReShape Lifesciences™

ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. For more information, please visit

CONTACTS:

Company Contact:                                       

Thomas Stankovich

Chief Financial Officer

949-276-6042

                                       

Investor Relations Contact:

Rx Communications Group

Michael Miller

(917)-633-6086



EN
10/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OBALON THERAPEUTICS INC

 PRESS RELEASE

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Finan...

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Progress Towards Completion IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate strategic update. First Quarter 2025 and Subsequent Highlights May 2025: Effected a 1-for-...

 PRESS RELEASE

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split Effective as of Commencement of Trading on May 9, 2025 IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-25 reverse stock split of the company’s common stock, which will be effective for trading purposes upon the commencement of trading on May 9, 2025. At that time, each 25 shares of issued and outstanding common stock and equivalents will be conv...

 PRESS RELEASE

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Di...

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional Vagal Stimulation Techniques IRVINE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will pre...

 PRESS RELEASE

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent...

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device IRVINE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/241,151, entitled, “Intragastric Device.” When iss...

 PRESS RELEASE

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S....

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Patent Enables Equivalent Efficacy with 10 times Lower Energy Consumption Than Current Device Fully Compatible with Standard Implantable Pulse Generators, Enabling Cost-Effective Development IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, to...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch